Sumatriptan Tablet
Product Images NDC 55700-899

4 FDA label images from Quality Care Products, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 55700-899). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Camscanner 02 18 2021 12.40 1)

Image Description (Camscanner 02 18 2021 12.40 1)
Label for Sumatriptan Tablets USP 100 mg oral tablets in a packaging of 9 unit-dose tablets. Labeled by Quality Care Products, LLC, with distribution by Aurobindo Pharma USA, Inc. The label includes storage warnings and manufacturer contact information.*
FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
A line graph depicting the estimated probability of response over time in minutes from the initial dose for Sumatriptan at dosages of 25 mg, 50 mg, and 100 mg, compared with a placebo. The y-axis represents the estimated probability of response in percentages and the x-axis represents time up to 240 minutes.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
A line graph depicting the estimated probability of relapse or remediation over time in hours from initial dose for different doses including placebo, 25 mg, 50 mg, and 100 mg. The y-axis represents the estimated probability, while the x-axis shows time in hours, illustrating how each treatment group progresses over a 24-hour period.*
FDA Label Image

Chemical Structure (Sumatriptan Str)

Chemical Structure (Sumatriptan Str)
Chemical structure of Sumatriptan Succinate, showing the molecular arrangement of its atoms including indole ring, sulfonamide group, and succinate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.